3SOF

Price 15.35

CEO Tim Healy told EnergyTechStocks.com on 8-19-08 that EnerNOC's power monitoring and energy procurement business is also growing rapidly. "The dialogue has shifted," he said, meaning more businesses want EnerNOC to drill down into how they consume electricity in order to eliminate costly inefficiencies.

While Healy said that first half revenue from monitoring and procurement services had surged to about $2.8 million compared with about $400,000 in the prior-year period, he indicated that he thinks this segment of EnerNOC's business may experience even sharper growth in the coming months. He told EnergyTechStocks.com that in just the last six or so weeks, interest in EnerNOC's monitoring services has "skyrocketed," in part because, thanks to a bigger R&D budget, EnerNOC now has more sophisticated algorithms capable of going "deeper and deeper into customer facilities" to find where power is being wasted.

I've been buying ENOC for the last week. This was a 50.00 stock 10 month's ago. Lot's of good news.

EnerNOC raises 2008 revenue view,

LOS ANGELES, Aug 7 (Reuters) - Energy efficiency company EnerNOC Inc (ENOC.O: Quote, Profile, Research, Stock Buzz) reported a narrower-than-expected quarterly loss on Thursday and raised its revenue outlook for the year on strong demand for its services, sending shares up nearly 12 percent in extended trading.

The second-quarter net loss was $10.4 million, or 54 cents a share, compared to a net loss of $8.2 million, or 74 cents a share, a year ago.

Wall Street analysts, on average, had been expecting a loss of 57 cents per share, according to Reuters Estimates.

Revenue nearly doubled to $23.7 million, above analysts' average estimate of $19.4 million, according to Reuters Estimates. In the same period last year, EnerNOC recorded revenue of $12 million.

EnerNOC, which helps utilities and grid operators curb and control peak electricity demand, raised its 2008 revenue view to between $101 million and $107 million. It previously expected revenue of $99 million to $105 million.

EnerNOC said it still expects to generate positive cash flow from operations in the second half of 2009 and record its first full year of profitability in 2010.

During the second quarter, EnerNOC increased its demand response megawatts under management by 141 MW to 1,643 MW.

EnerNOC shares rose to $15.75 in extended trading after closing at $14.08 on Nasdaq. (Reporting by Nichola Groom; Editing by Andre

EnerNOC upgraded by Ardour Capital
http://finance.yahoo.com/q/ud?s=ENOC



EnerNOC Delivers Over 100% Performance in First Canadian Demand Response Event
http://biz.yahoo.com/bw/080820/20080820005469.html?.v=1

Insider buys on 8-19-08
http://www.insiderscoop.com/ViewFiling/ViewFiling.aspx?accessionNo=0001179110-08-015527

CYTR looks a little over extended now IMO. Sold all @ 3.00. Nice run from 1.31. Will watch for a pullback for re-entry.

CYTR making new 52 week highs @2.67

CEO of CytRx Subsidiary, RXi Pharmaceuticals, to Participate on RNAi Panel at Mass High Tech BioForum
BusinessWire - January 29, 2007 8:30 AM ET
   

Related Quotes
Symbol   Last Chg
CYTR Trade 2.64 +0.09
Real time quote.
 
CytRx Corporation's (NASDAQ:CYTR) majority-owned subsidiary, Worcester, Massachusetts-based RXi Pharmaceutical Corporation (RXi), today announced that Chief Executive Officer Tod Woolf, Ph.D. will present at the Mass High Tech (MHT) 5th annual BioForum on a panel titled, "RNAi: Talking Outloud About Gene Silencing." Scheduled to join Dr. Woolf on the panel will be senior executives from Alnylam Pharmaceuticals, Inc. and Novartis Institute for BioMedical Research, Inc. Topics covered during the panel discussion will include best practices in RNAi research alliances, future RNAi applications and RNAi's impact on industry and academia.

The 5th annual BioForum is being held Thursday, February 1, 2007 from 5:30 p.m. to 9:00 p.m. in Cambridge, Massachusetts at UK Trade and Investment. For additional information about this conference and/or registration information, please visit http://masshightech.bizjournals.com/masshightech/event/2931.

The Mass High Tech business journal focuses on the business and technology challenges in bringing products and services into the marketplace. More than 67,000 MHT readers each week learn about companies and trends that affect the region before they appear in mainstream business publications and the daily newspapers. MHT focuses on intellectual property protection, access to capital, workforce skills and regulatory issues.

About CytRx Corporation

CytRx Corporation is a biopharmaceutical research and development company engaged in the development of high-value human therapeutics. The Company owns three clinical-stage compounds based on its small molecule "molecular chaperone" co-induction technology. In September 2006 CytRx announced that arimoclomol was shown to be safe and well tolerated at all three doses tested in its Phase IIa clinical trial in patients with ALS. The Company plans to enter a Phase IIb clinical trial with arimoclomol in ALS in the third quarter of 2007, subject to U.S. Food and Drug Administration (FDA) approval. The FDA has granted Fast Track designation and Orphan Drug status to arimoclomol for the treatment of ALS. Also in September 2006, CytRx announced receipt of $24.5 million in a non-dilutive agreement with the privately funded ALS Charitable Remainder Trust to fund continued arimoclomol development for the treatment for ALS in return for a 1% royalty from potential worldwide sales of arimoclomol for the treatment of ALS. The Greater Los Angeles Chapter of The ALS Association is the charitable beneficiary of the ALS Charitable Remainder Trust. For more information on the Company, visit CytRx's Web site at www.cytrx.com.

About RXi Pharmaceuticals Corporation

Massachusetts-based RXi is a biopharmaceutical research and development company that will focus on developing RNAi-based therapeutics for the treatment of human disease. RXi's initial focus will be on neurodegenerative diseases, oncology, type 2 diabetes and obesity. RXi has licenses to a diverse series of early patents and patent applications that were filed from 1998 to 2006 in the areas of RNAi target sequences, RNAi chemistry and RNAi delivery.

Forward-Looking Statements

This press release may contain forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Such statements involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements, including risks or uncertainties described in CytRx's most recently filed SEC documents, such as its most recent annual report on Form 10-K, all quarterly reports on Form 10-Q and any current reports on Form 8-K filed since the date of the last Form 10-K. All forward-looking statements are based upon information available to CytRx on the date the statements are first published. CytRx undertakes no obligation to publicly update or revise any forward- looking statements, whether as a result of new information, future events or otherwise.

SOURCE: CytRx Corporation

CEOcast, Inc. (for CytRx Corporation)
Dan Schustack, 212-732-4300
[email protected]
< Return to Previous

Quote from: pompano on January 12, 2007, 09:01:53 PM
This stock is very hot, broke out of its downtrend and is definitely on its way to the mid 3s.  I  highly recommend this stock.

You may be right On our way  new high today 2.61.

Futuremedia Regains Compliance With Nasdaq Listing Requirements
PR Newswire - January 22, 2007 8:36 AM ET
   

Related Quotes
Symbol   Last Chg
FMDAD Trade 2.33 0.00
Real time quote.
 
Futuremedia plc (Nasdaq: FMDAD) a leading learning and brand communications company, today announced that it received a Nasdaq Staff Letter, dated January 19, 2007, advising that the Company regained compliance with the minimum bid price requirement for continued listing found in the Nasdaq Marketplace Rules.

As previously announced on July 20, 2006, Futuremedia had received a Nasdaq Staff Deficiency letter, indicating that the Company was not in compliance with the minimum bid price requirement of $1.00 per American Depositary Share required by Nasdaq. During the subsequent compliance period provided under the Nasdaq Marketplace Rules, the closing bid price of the Company's ADSs has been at $1.00 per ADS or greater for at least 10 consecutive business days and Futuremedia has therefore regained compliance with the Nasdaq Marketplace Rules.

CytRx Corporation Subsidiary, RXi Pharmaceuticals, Obtains Option to License All Unrestricted Therapeutic RNAi Technologies Developed in the Next Three Years by the University of Massachusetts Medical School
BusinessWire - January 16, 2007 8:30 AM ET
   
 
CytRx Corporation (NASDAQ: CYTR) today announced that RXi Pharmaceuticals Corporation (RXi), a majority-owned subsidiary of CytRx, has entered into a master agreement with the University of Massachusetts Medical School (UMMS) that provides RXi option rights to license all unrestricted therapeutic RNAi technology developed at UMMS over the next three years, in return for cash payments and equity. RNAi has been shown to effectively interfere with the expression of targeted disease-associated genes with great specificity and potency.

Following disclosure by UMMS of new, unrestricted RNAi technologies, RXi will have the right, by making a specified cash payment to UMMS, to acquire an option to negotiate on an exclusive basis with UMMS to obtain a worldwide, exclusive license to the disclosed technology on commercially reasonable terms. The option rights are contingent upon RXi's receipt of working capital funding in the coming months. Financial terms were not disclosed for competitive reasons.

Since the co-discovery of RNAi by UMMS scientists in 1998, UMMS has played a leading role in developing potential RNAi therapeutics. RXi is already a licensee to many of these UMMS technologies.

"With this agreement, we gain access to new RNAi technologies developed at UMMS - the birthplace of RNAi. This agreement creates an excellent opportunity for RXi to license leading-edge breakthroughs in RNAi. Technology that we may acquire under this arrangement will further expand our already impressive portfolio of licenses to therapeutic RNAi intellectual property," said Tod Woolf, Ph.D., President and CEO of RXi.

Quote from: for3J1M on January 10, 2007, 12:08:48 AM
I just noticed the pop on cytr  i missed the news this morning.

http://news.moneycentral.msn.com/ticker/article.aspx?Symbol=US:CYTR&Feed=BW&Date=20070109&ID=6326635

stocks2watch2, looks like you are heading towards that year to date high!

We did it,just broke out to new 52 week high of 2.33.

CytRx Corporation Subsidiary, RXi Pharmaceuticals, Licenses ``Nanotransporters'' and Other RNAi Discoveries from the University of Massachusetts Medical School
BusinessWire - January 11, 2007 8:30 AM ET
   

Related Quotes
Symbol   Last Chg
CYTR Trade 2.08 0.00
Real time quote.
 
CytRx Corporation (NASDAQ:CYTR) today announced that RXi Pharmaceuticals Corporation (RXi), a majority-owned subsidiary of CytRx, has entered into significant new agreements with the University of Massachusetts Medical School (UMMS) to license RNA interference (RNAi) intellectual property for all therapeutic applications. RNAi has been shown to effectively interfere with the expression of targeted disease-associated genes with great specificity and potency, and was co-discovered by 2006 Nobel Laureate Dr. Craig C. Mello, who is expected to become a scientific advisor of RXi pending institutional approval. The agreements include an exclusive therapeutic license with rights to sublicense for nanotransporters, which have been shown to deliver intact RNAi to a number of tissues in animal models. The licenses are contingent upon RXi's receipt of working capital funding in the coming months. Financial terms were not disclosed for competitive reasons.

Tod Woolf, Ph.D., CEO of RXi, stated, "The scientists that founded RXi realized long ago that delivery technology was the key to systemic administration of RNAi. The nanotransporters are the culmination of work carried out since 2003 by Dr. Tariq Rana of UMMS. This new technology, together with our existing RNAi-based intellectual property licenses acquired from CytRx, extraordinary scientific advisors and proven management team provides the foundation required to establish RXi as a pre-eminent company focused exclusively on the RNAi field. With Merck's acquisition of Sirna Therapeutics, RXi expects to compete primarily with industry leader Alnylam Pharmaceuticals as a company dedicated to developing and commercializing RNAi therapeutics. While other competitors have sought collaborators to obtain systemic delivery of RNAi, RXi now has its own potential enabling delivery technology," added Dr. Woolf.

"If RXi is able to offer a new method for treating a broad range of diseases, RNAi therapeutics could become as important as small molecules and antibody drugs," said Steven A. Kriegsman, President and CEO of CytRx.

Licensed Nanotransporter Technology

Tariq M. Rana, Ph.D., Professor and Founding Director of the Program in Chemical Biology at UMMS and developer of the nanotransporters, has reported activity with RNAi delivered with nanotransporters in mouse models at 1 milligram per kilogram - an exceptionally favorable dose. The nanotransporters are highly uniform in structure and are readily formulated by simply mixing with RNAi compounds. Results of this research were presented at the 2006 Keystone Conference.

The RXi licensed technology also includes compounds for the potential treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) that can be delivered locally to the central nervous system. The ability to control gene expression in the central nervous system has potentially far-reaching implications for the treatment of a number of neurodegenerative diseases. In addition, the technology includes methods of targeting point mutations with RNAi that may be useful in targeting mutations that cause certain cancers and genetic diseases.

Quote from: rickjust on December 13, 2006, 11:44:14 AM
hi melf,
yes the rally back to 384 came on good volume .  let's see where it finishes the day. back to 369 . tomoorow 11am is earnings
maxi

Looks like earnings are to be released Before the markets open, and 11:00 is the cc.
Just watching I have no position in XNN, just wanted to correct the time. Good Luck

Xenonics Holdings, Inc. Fiscal Year End Conference Call Invitation
PR Newswire - December 11, 2006 9:00 AM ET
   

Related Quotes
Symbol   Last Chg
XNN Trade 3.59 -0.13
Real time quote.
 
Xenonics will report results for fiscal year end 2006, ended September 30, 2006, on Thursday, December 14, 2006 at approximately 5:30 a.m. EST. A conference call has been scheduled that morning at 11:00 a.m. EST.

    To participate, please dial in at least five minutes before the call
begins.

            SUBJECT:               Third Quarter Earnings
            CHAIRPERSON:           Alan Magerman, Chairman
            DATE:                  Thursday, December 14, 2006
            TIME:                  11:00 a.m. EST
            PHONE NUMBER:          (866) 825-3308
            PASS CODE:             # 93525688

A simultaneous webcast of the conference call can be accessed from www.earnings.com. A replay will be available after 1:00 p.m. EST at this same Internet address.

SOURCE Xenonics Holdings, Inc.

Valerie V. Vekkos of Xenonics Holdings, Inc., +1-760-438-4004, or
[email protected]
http://www.earnings.com

Healthcare Technologies Ltd. Regains Compliance With Nasdaq Minimum Bid Price Requirement
PR Newswire - December 13, 2006 5:17 AM ET
   

Related Quotes
Symbol   Last Chg
HCTL Trade 2.01 0.00
Real time quote.
 
Healthcare Technologies, Ltd. (NASDAQ: HCTL) announced that on December 12, 2006, it received a notice from the Nasdaq Capital Market indicating that the Company has regained compliance with Nasdaq Marketplace rule 4320(e)(2)(E)(i) (the "Bid Price Rule") because the closing bid price per share for its ordinary shares has been above $1.00 per share for more than 10 consecutive trading days. As a result, the Company has decided not to proceed with the previously announced proposal to effect a reverse stock split of the Company's ordinary shares.

About Healthcare Technologies

Healthcare Technologies through it subsidiaries and affiliate, Gamidor Diagnostics (1984) Ltd., Danyel Biotech Ltd. and Savyon Diagnostics Ltd., specializes in development, manufacturing and marketing of clinical diagnostic test kits and provides services and tools to diagnostic and biotech research professionals in laboratory and point of care sites worldwide.

Looks like it might have bottomed, I bought some @ an average 3.58.

Nymox has patent rights covering novel treatments for E. coli contamination and infection as well as other anti-bacterial treatments, including three issued U.S. patents, other international versions of these patents, as well as numerous pending patent applications both in the U.S. and abroad.

This could be huge with all the recent ecoli scares,

Nymox NXC-4720 Reduces E. Coli Contamination By 99%
BusinessWire - December 12, 2006 10:09 AM ET
   

Related Quotes
Symbol   Last Chg
NYMX Trade 3.85 +0.60
Real time quote.
 
Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is developing is developing NXC-4720, the Company's innovative new product targeting E. coli O157:H7 food poisoning at its source: the contamination of food products. Studies have shown that NXC-4720 is capable of reducing the level of E. coli O157:H7 contamination by over 99%.

Recent outbreaks of E. coli O157:H7 food poisoning highlight the vulnerability of the U.S. food supply chain and food industry to this serious public health hazard. As of December 10, 2006, 61 persons in northeastern U.S. had reported sick as a result of E. coli O157:H7 food poisoning with 50 requiring hospitalization. Preliminary results point to contamination of green onions. An earlier outbreak of E. coli O157:H7 contamination of fresh spinach in September 2006 left three people dead and over 100 people hospitalized. Children and the elderly are particularly at risk for the effects of this serious illness.

Nymox has patent rights covering novel treatments for E. coli contamination and infection as well as other anti-bacterial treatments, including three issued U.S. patents, other international versions of these patents, as well as numerous pending patent applications both in the U.S. and abroad.

Despite efforts to improve the safety of the food supply system, outbreaks of potentially deadly E. coli O157 food contamination remain common, both in the U.S. and around the world, including England, Ireland, France, and Canada. The Centers for Disease Control (CDC) estimates that E. coli O157 infections cause 73,000 illnesses annually in the U.S. alone, resulting in more than 2,000 hospitalizations and 60 deaths. A recent study by the U.S. Department of Agriculture estimated that the annual cost of illness due to E. coli O157 was $404 million, including $370 million for premature deaths: Frenzen PD et al, Journal of Food Protection 2005; 68:2623-2630.

More information about Nymox is available at www.nymox.com, email: [email protected], or 800-936-9669.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. The conduct of clinical trials and the development of drug products involve substantial risks and uncertainties and actual results may differ materially from expectations. Promising early results do not ensure that later stage or larger scale clinical trials will be successful or will proceed as expected. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.

SOURCE: Nymox Pharmaceutical Corporation

Nymox Pharmaceutical Corporation
Roy Wolvin, 1-800-93NYMOX
www.nymox.com

Thanks, I'm a little dissapointed in todays trading....Very low volume. I'm holding for now, I still think 1.70 was pretty close to the bottom. Looks like we did ok on HSOA again.

I've been watching HCTL since the big 250% run up on 11/29 where it opened @ 1.24 and shot up to 4.30, it has dropped back to the 1.70's . It looks like the bottom might be in.I bought some in the 1.70's yesterday and buying more today.This is a low float 2.8 mil. share stock so it can move fast.Here is the news that made it run on 11/29/06.

Looks like I timed this pretty good
Up 19% @ 2.07